Biotest

Biotest EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of Biotest (BIO.DE) as of Nov 5, 2026 is 59.28. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -53.42 — a change of -210.97% (higher).

EV/FCF

59.28

YoY

-210.97%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Biotest is 2024 59.28 . EV/FCF (Enterprise Value to Free Cash Flow) of Biotest was 2023 -53.42 . It decreases by -210.97% higher compared to the previous year.

The Biotest EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-24.04 EUR
Jan 1, 2018
-15.11 EUR
Jan 1, 2019
-24.83 EUR
Jan 1, 2020
-39.75 EUR
Jan 1, 2021
112.70 EUR
Jan 1, 2022
-26.71 EUR
Jan 1, 2023
-53.42 EUR
Jan 1, 2024
59.28 EUR
The Biotest EV/FCF history
YEAREV/FCFYoY
59.28-210.97%
-53.42+99.98%
-26.71-123.70%
112.70-383.50%
-39.75+60.08%
-24.83+64.34%
-15.11-37.14%
-24.04+15.69%
-20.78-15.99%
-24.73-4.65%
-25.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

EV/FCF (Enterprise Value to Free Cash Flow) of Biotest is 59.28 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Biotest changed from -53.42 to 59.28, representing a -210.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Biotest since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Biotest with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biotest

All Key Metrics — Biotest